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1. Introduction  
Psychological interventions are now well established as a core part of modern pain 
practice.  Randomized controlled trials (RCT) of psychological treatment for chronic pain 
first appeared in the 1970s and considerable effort, skill, and sophistication have been 
applied to establishing the evidence of effectiveness [26]. Over the last two decades  we and 
others have conducted systematic reviews and meta-analyses of psychological interventions, 
predominantly cognitive behavior therapy (CBT), for chronic pain [3; 6; 8; 16; 17; 27; 40].  
Meta-analysis facilitates the emergence of underlying patterns in data by controlling the bias 
and error inherent in individual studies. These meta-analyses suggest that, overall, CBT has 
a beneficial average effect for a range of outcomes, principally disability, depression, and 
pain experience.  Evidence of harms is not available.  Although the headline effect is 
positive, current analyses are limited to average results and conclusions are typically 
confined to the general.  
The aim of this topical review is to consider the next steps in developing and 
evaluating psychological treatments for chronic pain.  In this examination we take as our 
‘unit-of analysis’ the meta-analyses rather than individual RCTs.  We briefly summarize the 
results of the meta-analyses, their benefits and limits and then offer directions for improving 
the next generation of studies.  We argue that we have reached a critical point in the 
evolution of psychological interventions and a paradigm shift is now needed in how we 
investigate treatment efficacy, effectiveness, and harm. 
2. Evidence from meta-analysis 
Our first meta-analysis [27], showed CBT to be more effective (comparing groups 
post-treatment) than no-treatment/treatment as usual (TAU) for outcomes of pain, pain 
experience, cognitive coping and appraisal, behavioral expression of pain, mood/affect, and 
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social role functioning, with a median effect size ES(d) of 0.5.  There was marginal evidence 
that CBT was superior to other active treatments.  In later analyses, using improved 
methods, CBT remained superior to no-treatment/TAU, but the magnitude of d diminished 
to around 0.2 [8; 40]; similar to effect sizes in other meta-analyses for mixed chronic pain [33] 
low back pain [16; 17], fibromyalgia [3; 11; 14], and arthritis [6].  The smaller recent effect 
sizes  are likely due to improvements in the control of bias such as a stricter criterion for 
entry on individual study sample size [30].  The methodological quality in the design of 
trials, including risk of bias, improved over time, but treatment quality did not (see figure 2 
in [26]).  This held after excluding many trials for inadequate/insufficient psychotherapeutic 
content.  Despite having more and better designed trials for meta-analysis, the picture 
remains unclear.  Half of the comparisons showed no effect of CBT and half showed weak 
effect sizes of unknown clinical significance on pain, mood, disability and catastrophic 
thinking outcomes [40].  The clarity of any overall effect is muddied by three main sources: 
(i) sample, measure, and treatment heterogeneity; (ii) unexplained variation of outcome 
reporting across studies; and (iii) theoretical imprecision.  
In summary, current meta-analyses indicate that psychological treatments are likely 
to be effective. However, as more studies are produced and added to meta-analyses, the 
results are effectively being diluted by the addition of poorly conceived, conducted, and 
reported trials.  The signal to noise ratio is shrinking.  Meta-analysis cannot control for poor 
primary studies or poor reporting [20].  Additional trials that are atheoretical, biased, single 
center, and enthusiasm-driven will make summary and interpretation increasingly difficult.  
We suggest that, without radical change, simply adding further trials will not help us to 
improve treatment effectiveness nor help answer research questions.  
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This is not a counsel of despair.  We are not arguing for the abandonment of the 
program of developing and testing psychological treatments for chronic pain.  This would 
be a misreading: psychological therapies for the management of chronic pain offer 
worthwhile and promising treatments.  We seek rather to build on the evidence base, but 
suggest changing our methods of investigation [22; 32].  If we do not improve the methods 
of primary investigation and learn from the trial developments in other areas of pain 
investigation then we will achieve only confusion [32]. 
3. The complexity of chronic pain 
Chronic pain is complexly maintained and its treatment resistance should not 
surprise us.  In fact recently it has been argued that analgesic failure is to be expected and 
should be a guiding treatment principle of all chronic pain treatment [21].  Patients present 
with disability established over many years.  Many of the trials present treatments of brief 
duration, sometimes delivered by personnel trained just for that trial: good clinical outcomes 
are rather less likely from dilute/short treatments delivered by inexperienced staff to 
severely distressed patients.  Perhaps we have underestimated the complexity of behavior 
change and the social and psychological influences that maintain disability in chronic pain 
patients [4].  Even if pain can be modulated by non-psychological methods, the complexity 
of psychological and behavioral adaptation means that the interruptive, interfering and 
identity-distorting impacts of pain are no longer functionally related to the immediate 
experience of pain but are controlled by contextual behavioral, social and cognitive factors 
that require therapeutic attention [10; 18; 23].  
4.  Heterogeneity in patient populations and treatment complexity 
Many trials have mixed patient samples made up of patients with many and varied 
diagnoses.  Critics have argued for greater specificity and trials are emerging of single-
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diagnosis patient samples.  Identifying groups of patients by disease or disorder may aid 
evidence-based translation to clinical practice, but psychological profiles are often 
orthogonal to medical diagnosis [9].  Diagnostic group membership is largely unhelpful in 
explaining patient pain behavior or in guiding treatment decisions.  Entry criteria for trials 
rarely specify levels of distress or disability other than to exclude participants with 
intellectual limitations, overt symptoms of psychosis or addiction.  The distribution of scores 
on measures of depression and distress covers the full spectrum.  A psychologically-
informed characterization of patients might facilitate better targeted and more effective 
treatment but the optimal method for patient group determination is still under debate [29; 
36; 38].  Many of the trials entered into meta-analyses comprise pragmatic mixes of 
treatment content.  The rationale for treatment choice and blend in multicomponent 
treatments is often unreported, and perhaps of more concern, there is often a disparity 
between the aims of treatment, the actual treatment content, and outcomes reported.  This 
makes it difficult to discern which components of treatment contribute to specific changes.  
Component dismantling studies offer an illusion of identifying ‘active ingredients’ but 
cannot achieve sufficient power to calculate the effects of each component on each outcome 
[12].  It is worth noting that within the general field of psychotherapy it is difficult to obtain 
effect sizes significantly different from zero for the difference between treatment packages 
with and without a putatively effective component [1]. 
5. Outcome measures and measurement 
Historically, psychological treatments have utilized outcomes with continuous 
measures that are expressed by Cohen’s ES(d) and its variants.  This has inherent practical 
limitations and implications.  The between-group ES of 0.2, typical of recent meta-analyses, 
is unhelpful in communication with patients who want to know ‘what are my chances of 
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getting better?’  Replying that ‘the average person in the treated group is at the 58th 
percentile (or 69th percentile when (d) = 0.5) of the untreated group’, although accurate is 
unhelpful [24].  Most trials report statistical rather than clinical significance.  Rarely do trials 
report binary outcomes based on clinical significance criteria [24; 29].  Consequently we have 
no basis on which to estimate the number of successfully treated people.  Pre-post treatment 
effect sizes are also modest (~ 0.4) and do not approach the value of around 1.5 desired by 
patients [31; 34].  Finally, although diverse measures are reported in trials, it is not clear that 
they necessarily coincide with the interests of patients [2; 35]. Nor are adverse effects or 
dropout rates adequately recorded [28].  This may reflect inadequate preparation for 
treatment, or worse a failure of equipoise in which investigators simply do not expect 
failure.  
6. The next steps 
The treatment of chronic pain remains a challenge whether the primary aim is 
analgesic or rehabilitative.  The success rates (and effect sizes) for psychological treatments 
are similar to those reported for pharmacological and surgical interventions [5; 15].  What is 
different from the evidence base for non-psychological interventions is that as more trials of 
psychological treatments are published clarity becomes more not less elusive.  Additional 
low-quality trials of minor variations in therapy will not solve the problems outlined here 
and will only add noise.  A paradigm shift is necessary and long overdue. Three major 
advances are needed and we invite consideration and debate. 
First, we encourage the design of theoretically coherent evaluations and trials.  
Precise testable models are needed that link specific treatment procedures with specific 
psychological changes leading to hypothesized specific outcomes.  Therapy needs to be 
based on explicit theoretical models that guide choice of content, dose, timing and quality of 
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treatment, and the choice of specific outcomes.  There are examples of useful theory.  The 
evidence for graded exposure has been developed in a clinical context using single case 
methodology to systematically replicate and test its component processes [37].  The 
theoretically sophisticated functional affective-motivational model of attention and pain has 
been extensively explored and tested in laboratory settings [19].  It is markedly different 
from the limited channel capacity model upon which most clinical interventions for 
attention modulation are based [25] and is ripe for translation. 
Second, we propose a standardizing of key features of methodological quality and 
bias. In particular we should adopt the IMMPACT criteria on measurement domains and 
measurement tools [7].  We should judge small-n RCTs (including those labeled ‘feasibility’, 
‘preliminary’, and ‘exploratory’) as low quality[13] and encourage studies with adequate 
control over bias.  We need clear articulation of the severity of patient complaint using a 
shared language of the extent of disability, distress, and alterable behavior [39].  Critical to 
bias control will be an honest appraisal of the common lack of equipoise in psychological 
trials, and the requirement at the very least for the transparent reporting of therapist 
allegiance.  Finally, trials that do not measure or report adverse events should be considered  
fundamentally flawed.  
Third, alternatives to the randomized controlled trial should be considered.  
Rowbotham et al [32] recently argued that to properly address the clinical effectiveness of an 
efficacious treatment we need to invest in large scale observational and translational studies.  
This is relevant also in psychological interventions, and in particular for the benchmarking 
of achievable outcomes in regular clinical practice.  Single case methodologies are also 
infrequently used and have promise [37].  Advances in secondary data analysis are also 
relevant and analysis at the patient level across trials may be particularly relevant for 
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indirect comparisons between treatments. Responder analyses are also promising and 
should be explored.  Both will rely on open access to data. 
We argue that it is time for a radical change in how we design treatments, and study 
their effectiveness. A paradigm shift is essential.  We have gone as far as we can with the old 
models. The next generation of studies will need to raise the bar on quality. Studies that do 
not measure adverse events should be considered unethical. Studies that do not control 
therapist allegiance should be considered flawed. Studies that are small should be ignored.  
The next studies will better define homogenous samples of patients, and will match key 
sample features to treatment content and outcome assessment.  Access to data at an 
individual patient level will allow for responder analyses. And, access to larger datasets on 
community studies will allow for effectiveness studies at scale. Future systematic reviews 
will also lead improvement by being explicit and transparent about trial entry. Evidence will 
be graded with tools that recognize the influence of bias in individual trials, and innovative 
methods of portraying the results of comparative effectiveness studies to different 
stakeholders will improve their relevance. 
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